Home World News Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab... World News Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 251 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of... March 21, 2023 Are differences in treatment driving variation in ovarian cancer survival internationally? August 11, 2020 Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback January 4, 2022 EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... March 16, 2021 Load more HOT NEWS Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... Unravelling the mystery of Barrett’s oesophagus Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable...
